Introduction to Cancer Biology Vocabulary

Student Introductions and Course Context

• Personal Backgrounds and Class Preferences:

  • Scout: Prefers music by Turnpike Troubadours; does not frequently watch movies or television shows.

  • Sarah: Listens to various genres with a preference for Zach Bryan and country music; favorite television show is Grey's Anatomy, along with trending media.

  • Maddie: Listens predominantly to country music, with Vincent Mason as current favorite artist; watches Dancing with the Stars and Dancing with the Stars: Next Pro (a spin-off show where professional dancers compete in challenges to earn spots on the primary show).

  • Unnamed Student 1: Enjoys country music; current favorite show is The Following on Netflix.

  • Brogan: Listens to country music; favorite movie is Private Benjamin; routinely rewatches The Office.

  • Marley: Prefers R&B music; enjoys documentaries and psychological horror/scary movies.

  • Erin: Listens predominantly to pop music; favorite television show is Girls.

  • Gianna: Listens to Christian music; favorite show is Beast Games by MrBeast (a competitive annual show starting with $100\, individuals$ completing team and solo challenges).

  • Isabella: Music preference is Shinedown; favorite television show is Shameless.

  • Riley: Listens to older music including Abba; favorite film series is The Conjuring.

  • Siona: Listens to all music genres; frequently watches psychological thrillers.

  • Sydney: Prefers 2000s pop and R&B artists including Mary J. Blige (MJB), Usher, Kesha, and Michael Jackson; favors comedy films, specifically Madea movies.

  • Ava: Listens to R&B, folk, and early 2000s music; favorite show is Vampire Diaries.

  • Aggie: Currently listens to Malcolm Todd following a new album release; watches reality television including Big Brother.

  • Media Mentioned by Instructor: Listens to heavy metal/hard rock through family; currently watches Ted Lasso.

Fundamental Definitions in Cancer Biology

• Tumor vs. Cancer Distinction:

  • Tumor (Neoplasm): An abnormal mass or growth of tissue. Benign tumors represent abnormal growths that remain regulated in their extent of division and do not invade surrounding tissues.

  • Cancer: A tumor characterized specifically by unregulated, uncontrolled cell division where cells continuously divide without responding to normal stop signals.

• Benign vs. Malignant Tumors (Three Key Distinctions):

  • Rate of Growth: Benign tumors grow slowly, whereas malignant tumors grow rapidly.

  • Metastasis and Encapsulation: Benign tumors are encapsulated by connective tissue and cannot metastasize; malignant tumors lack encapsulation and possess the capacity to metastasize throughout the body.

  • Cellular Morphology: Benign cells resemble normal parent cells, whereas malignant cells exhibit significant morphological abnormalities under microscopic examination.

• Etymology and Related Terminology:

  • Neoplasm: Derived from root words neo (meaning new) and plasm (meaning growth of cellular tissue); used interchangeably with the term tumor.

  • Tumorigenesis / Carcinogenesis: Derived from genesis (meaning beginning, start, or creation). Refers to the cellular and genetic origin, creation, or etiology of a new tumor or cancer.

  • Etiology: The underlying cause or origin of a specific disease state; critical for targeting treatments and establishing early detection protocols.

  • Malignant Transformation: The multi-step biological process wherein a normal cell undergoes genetic and phenotypic changes to transition into a cancerous cell. (In microbiology, transformation refers to the uptake and expression of exogenous DNA by a bacterial cell).

Genetic Mechanisms, BRCA1, and Cancer Phenotypes

• Genes and Alleles:

  • Gene: A specific sequence of DNA encoding a functional protein or trait.

  • Allele: A variant version of a gene contributing to genetic diversity within a population. Human somatic cells inherit $2\, alleles$ per gene (one paternal, one maternal).

  • Impact on Cancer Risk: Specific inherited alleles can increase, decrease, or have no effect on individual cancer susceptibility.

• BRCA1 Gene Function and Mutational Impact:

  • Functional BRCA1 Protein: Plays a crucial role in repairing double-stranded DNA damage.

  • BRCA1 Mutations: Non-functional or mutated BRCA1 alleles impair DNA repair efficiency. Unrepaired DNA damage accumulates during repeated cell divisions, significantly elevating the risk of developing breast and ovarian cancers.

  • Screening Panels: Genetic testing often uses multi-gene panels targeting up to $90\, genes$ associated with hereditary breast, ovarian, and colorectal cancers.

• Genotype vs. Phenotype in Oncology:

  • Genotype: The specific genetic constitution of an organism (e.g., harboring a heterozygous mutated BRCA1 allele).

  • Phenotype: The observable physical or physiological characteristics resulting from a genotype. In cancer biology, phenotype encompasses both microscopic cell appearance and clinical disease state (e.g., the cancer phenotype of a BRCA1 mutation is the clinical onset of breast or ovarian cancer).

• Microscopic Morphology:

  • Histological Diagnosis: Morphology is the study of form and structural shape. Pathologists and medical laboratory scientists evaluate microscopic tissue slides (such as H&E stained sections) to diagnose malignancy based on irregular nuclear and cellular shapes.

Classification and Taxonomy of Cancers

• Tissue Origins and Carcinomas:

  • Epithelial Cells: Cells forming the lining of skin, internal organs, and cavities. Due to continuous environmental exposure and high cell turnover, epithelial tissue gives rise to over $90\%$ of all human cancers (textbook estimates state $85\%$ to over $90\%$).

  • Carcinomas: Cancers of epithelial origin.

  • Adenoma vs. Adenocarcinoma: An adenoma is a benign tumor of glandular tissue; an adenocarcinoma is a malignant tumor arising from glandular tissue.

• Hematopoietic Cancers:

  • Hematopoietic Cancers: Cancers originating from blood-forming cells, accounting for approximately $10\%$ of all cancers.

  • Leukemias: Malignancies of white blood cells (leukocytes) floating within the bloodstream.

  • Lymphomas: Solid tumors arising within the lymphatic system and lymphoid organs.

  • Myelomas: Cancers originating from plasma cells (B-cell lineage) located within the bone marrow.

• Sarcomas and Neuroectodermal Cancers:

  • Sarcomas: Rare cancers arising from mesodermal germ layer tissues, including muscle, bone, fat, and cartilage connective tissue.

  • Neuroectodermal / Neuroepidermal Cancers: Cancers originating from neuronal and glial tissues within the central and peripheral nervous systems (e.g., brain tumors).

• Historical Naming Anomalies:

  • While benign tumors traditionally end in -oma and malignant epithelial tumors in -carcinoma, exceptions exist in oncology terminology (e.g., lymphoma, myeloma, and melanoma are highly malignant despite ending in -oma).

Cancer Epidemiology, Prevalence, and Global Health Disparities

• Cancer Diversity:

  • Identified Cancers: There are over $200\, distinct$ identified human cancers.

  • Biological Heterogeneity: Cancer is not a single disease, but a collection of distinct diseases requiring different therapeutic approaches. Universal or "blanket" cures are highly improbable because treatments targeting one cell type (e.g., myeloma) rarely translate directly to unrelated tissue types (e.g., pancreatic or lung cancer).

• Lifetime Prevalence:

  • Individual Risk: Approximately $1\text{ in }3\, individuals$ will develop cancer during their lifetime (statistically equivalent to $7\text{ out of }21\, students$ in a standard classroom).

• Triple-Negative Breast Cancer (TNBC):

  • Target Receptors: Conventional breast cancer treatment targets three primary cell-surface receptors:

  • Estrogen Receptor (ER)

  • Progesterone Receptor (PR)

  • Human Epidermal Growth Factor Receptor 2 (HER2 / EGF Receptor)

  • Therapeutic Challenge: Triple-negative breast cancer cells lack expression of all three receptors, making receptor-targeted therapies ineffective and necessitating aggressive systemic treatments.

• Global Disparities and Human Development Index (HDI):

  • Incidence Distribution: High Human Development Index (HDI) regions (e.g., North America, reporting $\\approx 1.5 \times 10^6\, annual\, cases$) report significantly higher cancer incidence rates compared to low HDI regions (e.g., Africa, with a population of $1.2 \times 10^9\, people$ vs. the United States with under $400 \times 10^6\, people$).

  • Disease Competition Paradox: In lower HDI countries, infectious, parasitic, and respiratory diseases represent primary causes of mortality at younger ages. In higher HDI countries, control of infectious diseases extends overall life expectancy, allowing individuals to survive into ages where cancer incidence peaks.

Cancer Trends, Detection, and Survival Analysis

• Mortality Comparisons (Heart Disease vs. Cancer):

  • Between $1975\text{ and }2007$, age-adjusted mortality from cardiovascular disease dropped precipitously due to medical and lifestyle interventions.

  • Over the same period, overall cancer mortality rates remained relatively flat despite significant advancements in detection and therapy.

• Demographics of Primary Cancers:

  • Male Incidence Leader: Prostate cancer.

  • Female Incidence Leader: Breast cancer.

  • Pancreatic Cancer Incidence: Accounts for approximately $3\%$ of new cancer cases in both males and females.

  • Primary Mortality Leader: Lung and bronchial cancer causes the highest absolute number of deaths in both men and women due to high resistance to current treatment regimens.

• Historical Mortality Trends and Lag Times:

  • Stomach Cancer: Mortality has declined steadily since the $1930\text{s}$ due to changes in food preservation and diet.

  • Lung Cancer and Tobacco Lag Time: Cigarette consumption in the United States peaked during the $1960\text{s}$, whereas lung cancer mortality peaked in the $1980\text{s}$. This demonstrates a $15\text{ to }20\, year\, lag\, time$ between carcinogen exposure and clinical cancer development.

• Lifespan Extension and Cancer Incidence:

  • Average Lifespan Shift: Average human lifespan in $1900$ was under $50\, years$; modern average lifespan approaches $80\, years$.

  • Longevity Impact: The additional $30\, years$ of life provide expanded time for somatic mutations to accumulate within host tissues, establishing cancer as predominantly a disease of aging.

• Survival Metrics (Pancreatic Cancer Case Study):

  • Standard Landmark: $5\, year$ survival without recurrence is clinically defined as disease remission/cure.

  • Overall Pancreatic Survival: The $5\, year$ survival rate across all stages is $11\%$.

  • Stage-Dependent Survival:

  • Localized Detection: $42\%$ $5\, year$ survival rate.

  • Distant Metastatic Detection: $3\%$ $5\, year$ survival rate.

  • Clinical Failure Factor: Pancreatic cancer is rarely symptomatic during early localized stages, leading to late-stage diagnosis after metastatic dissemination.

Biological Mechanisms of Cancer Cells and In Vitro Characteristics

• Immune Recognition of "Harmful Self":

  • Mechanism: Historically, immunotherapies were questioned because cancer cells derive from host tissue ("self"). Modern immunology establishes that the immune system recognizes "non-self", "self", and "harmful self".

  • Transformation Expression: Malignant transformation alters cellular surface markers sufficiently for immune cells to recognize transformed cells as "harmful self" and target them for destruction.

• In Vitro Properties of Transformed Cancer Cells:

  • Loss of Contact Inhibition: Normal adherent cells stop dividing when they form a monolayer and reach $100\%$ confluency on a culture flask surface. Cancer cells lose contact inhibition, continuing to divide and pile up into multi-layered foci.

  • Reduced Serum Requirement (Serum Independence): Normal cells require high concentrations of animal serum (supplying growth factors and hormones) to proliferate. Cancer cells produce their own autocrine signals and can proliferate in low-serum media.

  • Altered / Rounded Morphology: Normal adherent cells display flattened, specialized shapes (e.g., fibroblastic or polygonal). Cancer cells lose structural differentiation, detaching partially and rounding up in culture.

  • Anchorage Independence: Normal non-hematopoietic cells undergo apoptosis if detached from an extracellular matrix (anchorage dependence). Cancer cells survive and divide without substrate attachment, enabling semi-solid agar suspension growth and systemic metastatic potential.

Questions and Audience Discussion

• Discussion on Mutagen vs. Carcinogen Distinction:

  • Prompt: Can an agent be a mutagen without being a carcinogen, or vice versa?

  • Response: Yes. A mutagen alters DNA sequences, whereas a carcinogen induces functional cancer development. Sodium azide is a potent laboratory mutagen that induces specific DNA mutations, but it does not mutate oncogenes or tumor suppressors and is not a known carcinogen. Conversely, ethanol (alcohol) is an established carcinogen associated with multiple malignancies, but it is not a direct DNA-damaging mutagen.

• Discussion on Metastasis Speed and Detection Limits:

  • Prompt: What is the fastest rate at which a tumor can metastasize through the body?

  • Response: Rates vary based on vascularization. Once a malignant cell detaches, invades the extracellular matrix, and intravasates into a blood or lymphatic vessel, systemic dissemination occurs rapidly. However, metastatic cells often lie dormant at secondary tissue sites before proliferating into detectable tumors, rendering precise timing difficult to quantify with existing diagnostic technologies.

• Discussion on Pancreatic Cancer Therapeutic Advances:

  • Prompt: What are the details regarding recently approved pancreatic cancer treatments?

  • Response: Novel therapeutics approved by the FDA (such as targeted therapies discussed in recent medical news) extend median survival from approximately $7\, months$ to $13\, months$. While statistically significant and valuable for patient longevity, it highlights the clinical difficulty of achieving complete cures in advanced pancreatic malignancies.